Unlabelled: To clarify the role of leukocytes in reperfusion injury of preserved lung for lung transplantation, leukocyte depletion was performed and lung tissue generation of oxygen metabolites and histological evaluation were investigated.

Method: 12 mongrel dogs were utilized, divided into 2 groups. In group A, hilar-stripped left lung was submitted to 2 hour warm ischemia and 2 hour reperfusion. Blood filtration was performed three times using leukocyte filter. In group B, warm ischemia and reperfusion were performed without filtration. Lipid peroxidation products of lung tissue were measured by thiobarbituric acid assay. Tissue damage was estimated by wet/dry ratio and histological analysis. Results 1). Peripheral blood counts revealed that effective leukocyte depletion was obtained and leukocyte efflux from reperfused lung was observed in group A. 2) Significant increase of lung tissue oxygen metabolite generation after reperfusion was observed in group B, while no significant fluctuate of tissue MDA titers was noted in group A. Tissue damage estimated by histological analysis and wet/dry ratio were considered to be controlled in group A compared with group B. In conclusion, leukocyte depletion by in vivo use of leukocyte filter was effective for reperfusion injury of warm ischemic lung and oxygen metabolites may play a role in these process.

Download full-text PDF

Source

Publication Analysis

Top Keywords

leukocyte depletion
16
reperfusion injury
12
lung tissue
12
peripheral blood
8
injury warm
8
warm ischemic
8
lung
8
oxygen metabolites
8
warm ischemia
8
leukocyte filter
8

Similar Publications

Background: Metastatic spine tumor surgery (MSTS) is often complex and extensive leading to significant blood loss. Allogeneic blood transfusion (ABT) is the mainstay of blood replenishment but with immune-mediated postoperative complications. Alternative blood management techniques (salvaged blood transfusion [SBT]) allow us to overcome such complications.

View Article and Find Full Text PDF

Current advancements in cellular immunotherapy for autoimmune disease.

Semin Immunopathol

January 2025

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach by redirecting immune cells to correct the underlying autoimmunity. This review explores the latest advances in cellular immunotherapies for autoimmune diseases, focusing on various strategies, such as the use of chimeric antigen receptor (CAR) T cells, chimeric auto-antibody receptor (CAAR) T cells, regulatory T cells (Tregs), and tolerogenic dendritic cells (TolDCs).

View Article and Find Full Text PDF

A new twist on superantigen-activated autoimmune disease.

J Clin Invest

January 2025

Division of Rheumatology, Center of Excellence for Intestinal and Immunology Research, University of Alberta, Edmonton, Alberta, Canada.

Superantigen-induced (Sag-induced) autoimmunity has been proposed as a mechanism for many human disorders, without a clear understanding of the potential triggers. In this issue of the JCI, McCarthy and colleagues used the SKG mouse model of rheumatoid arthritis to characterize the role of Sag activity in inflammatory arthritis by profiling arthritogenic naive CD4+ T cells. Within the diseased joints, they found a marked enrichment of T cell receptor-variable β (TCR-Vβ) subsets that were reactive to the endogenously encoded mouse mammary tumor virus (MMTV) Sag.

View Article and Find Full Text PDF

Background: Programmed cell death ligand 1 (PD-L1) expression on immune cells is correlated with the efficacy of immune checkpoint inhibitor (ICI) therapy in various types of cancer. Platelets are important components of the tumour microenvironment (TME) and are widely involved in the development of many types of cancer including colorectal cancer (CRC). However, the role of PD-L1 positive platelets in ICI therapy for CRC remains unknown.

View Article and Find Full Text PDF

Rare Cell Population Analysis in Early-Stage Breast Cancer Patients.

Breast Cancer (Auckl)

January 2025

Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: Circulating rare cells participate in breast cancer evolution as systemic components of the disease and thus, are a source of theranostic information. Exploration of cancer-associated rare cells is in its infancy.

Objectives: We aimed to investigate and classify abnormalities in the circulating rare cell population among early-stage breast cancer patients using fluorescence marker identification and cytomorphology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!